Sandoz US News

sandoz_us_news.jpg

New interim data demonstrate Sandoz proposed biosimilar rituximab has equivalent efficacy to reference product

Holzkirchen, December 5, 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced data from the ASSIST-FL trial. The confirmatory safety and efficacy study shows GP2013 met its primary endpoint of overall response rate (ORR), demonstrating equivalence with the reference product, MabThera®*, in 629 patients. Results were presented at the 58th Annual Meeting of the American Society of Hematology (ASH).

Sandoz to donate up to USD 10 million of high-quality generic medicines annually to Americares to increase access to medicines

Princeton, New Jersey, November 22, 2016. Sandoz today announced a collaboration to increase access to medicines by donating up to USD 10 million of stock annually to Americares, a health-focused relief and development organization that responds to people affected by poverty or disaster with life-changing health programs, medicine and medical supplies.

Sandoz launches authorized generic version of Beyaz®

Sandoz today announced the U.S. market introduction of the authorized generic version of Beyaz® (drospirenone/ethinyl estradiol/ levomefolate calcium tablets and levomefolate calcium tablets) mg/0.02 mg/0.451 mg and 0.451 mg, by Bayer

Sandoz Careers

sandoz_careers.jpg

Our people are our greatest resource. We are always looking for new colleagues to share in our passion and commitment to making the world a healthier place.

 Learn more about a career with Sandoz in the US

 

Vets Hiring 300

Transitioning to civilian service soon? Consider a career with Sandoz, a Novartis company. Learn about our mission, and why you should explore being a part of our team.

  •  

     

     

Slideshow Background Images